Cargando…

Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months

OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationw...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Louise J, Moore, Julie S, Blighe, Kevin, Ng, Kok Yew, Quinn, Nigel, Jennings, Fergal, Warnock, Gary, Sharpe, Peter, Clarke, Mark, Maguire, Kathryn, Rainey, Sharon, Price, Ruth K, Burns, William P, Kowalczyk, Amanda M, Awuah, Agnes, McNamee, Sara E, Wallace, Gayle E, Hunter, David, Sager, Steve, Chao Shern, Connie, Nesbit, M Andrew, McLaughlin, James A D, Moore, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245291/
https://www.ncbi.nlm.nih.gov/pubmed/34187827
http://dx.doi.org/10.1136/bmjopen-2020-048142
_version_ 1783716087011999744
author Robertson, Louise J
Moore, Julie S
Blighe, Kevin
Ng, Kok Yew
Quinn, Nigel
Jennings, Fergal
Warnock, Gary
Sharpe, Peter
Clarke, Mark
Maguire, Kathryn
Rainey, Sharon
Price, Ruth K
Burns, William P
Kowalczyk, Amanda M
Awuah, Agnes
McNamee, Sara E
Wallace, Gayle E
Hunter, David
Sager, Steve
Chao Shern, Connie
Nesbit, M Andrew
McLaughlin, James A D
Moore, Tara
author_facet Robertson, Louise J
Moore, Julie S
Blighe, Kevin
Ng, Kok Yew
Quinn, Nigel
Jennings, Fergal
Warnock, Gary
Sharpe, Peter
Clarke, Mark
Maguire, Kathryn
Rainey, Sharon
Price, Ruth K
Burns, William P
Kowalczyk, Amanda M
Awuah, Agnes
McNamee, Sara E
Wallace, Gayle E
Hunter, David
Sager, Steve
Chao Shern, Connie
Nesbit, M Andrew
McLaughlin, James A D
Moore, Tara
author_sort Robertson, Louise J
collection PubMed
description OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationwide serological study. SETTING: Northern Ireland, UK, May 2020–February 2021. PARTICIPANTS: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. MAIN OUTCOME MEASURES: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. RESULTS: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). CONCLUSIONS: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting.
format Online
Article
Text
id pubmed-8245291
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82452912021-07-01 Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months Robertson, Louise J Moore, Julie S Blighe, Kevin Ng, Kok Yew Quinn, Nigel Jennings, Fergal Warnock, Gary Sharpe, Peter Clarke, Mark Maguire, Kathryn Rainey, Sharon Price, Ruth K Burns, William P Kowalczyk, Amanda M Awuah, Agnes McNamee, Sara E Wallace, Gayle E Hunter, David Sager, Steve Chao Shern, Connie Nesbit, M Andrew McLaughlin, James A D Moore, Tara BMJ Open Infectious Diseases OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationwide serological study. SETTING: Northern Ireland, UK, May 2020–February 2021. PARTICIPANTS: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. MAIN OUTCOME MEASURES: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. RESULTS: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). CONCLUSIONS: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting. BMJ Publishing Group 2021-06-29 /pmc/articles/PMC8245291/ /pubmed/34187827 http://dx.doi.org/10.1136/bmjopen-2020-048142 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infectious Diseases
Robertson, Louise J
Moore, Julie S
Blighe, Kevin
Ng, Kok Yew
Quinn, Nigel
Jennings, Fergal
Warnock, Gary
Sharpe, Peter
Clarke, Mark
Maguire, Kathryn
Rainey, Sharon
Price, Ruth K
Burns, William P
Kowalczyk, Amanda M
Awuah, Agnes
McNamee, Sara E
Wallace, Gayle E
Hunter, David
Sager, Steve
Chao Shern, Connie
Nesbit, M Andrew
McLaughlin, James A D
Moore, Tara
Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title_full Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title_fullStr Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title_full_unstemmed Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title_short Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
title_sort evaluation of the igg antibody response to sars cov-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245291/
https://www.ncbi.nlm.nih.gov/pubmed/34187827
http://dx.doi.org/10.1136/bmjopen-2020-048142
work_keys_str_mv AT robertsonlouisej evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT moorejulies evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT blighekevin evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT ngkokyew evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT quinnnigel evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT jenningsfergal evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT warnockgary evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT sharpepeter evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT clarkemark evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT maguirekathryn evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT raineysharon evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT priceruthk evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT burnswilliamp evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT kowalczykamandam evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT awuahagnes evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT mcnameesarae evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT wallacegaylee evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT hunterdavid evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT sagersteve evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT chaoshernconnie evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT nesbitmandrew evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT mclaughlinjamesad evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months
AT mooretara evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months